Shelf registration statement covering 1.5 mil. common shares filed with Securities & Exchange Commission. Proceeds will primarily be used to pay for recent Invenex and Bristoject acquisitions. In addition, Fujisawa will purchase 500,000 shares in a private transaction that will maintain its stake in LyphoMed at about 26.5%.
You may also be interested in...
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.